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INTRODUCTION
21 Endocannabinoid System (ECS)
The Endocannabinoid system (ECS) is a neuromodulatory network known to be
targeted by Δ9–tetrahydrocannabinol (Δ9–THC), it is the main psychoactive
component of marijuana also know as Cannabis Sativa (Anh, 2008).  Preparation of
cannabis extract have been used as recreational purposes but also as medicinal
agent   to affect appetite, pain, mood, motor control, memory, cognition, and
perception.  The Endocannabinoid signaling system is made up of  two G-protein-
coupled-cannabinoid receptors (CBRs) , that can be activated by small lipid
mediators, known as endocannabinoids (eCBs), and by Cannabis-derived drugs.
The endocannabinoids where found to be derivatives of arachidonic acid conjugated
with a polar head group, ethanolamine or glycerol, by amide (such as anandamide
or N-arachidonoylethanolamine (1), AEA), ester arachidonoylglycerol or 2‐AG
(2) and virodhamine (3)) or ether moieties (2‐arachidylglycerol or noladin ether
(4))
Among these lipid mediators, anandamide and 2-arachidonoylglicerol acid, a
relevant role have anandamide and 2-arachidonoylglicerol acid to their
pharmacology and metabolism.
Fig. 1 Structures of the cannabinoid receptor ligands anandamide (1), 2‐arachidonoylglycerol (2), virodhamine
(3) and noladin ether (4).
31.1 Endocannabinoid Receptors
Cannabinoid receptors (CBRs) are a class of cell membrane metabotropic receptors
belonging to the superfamily of G-protein-coupled receptors (GPCRs). As it is
common for  GPCRs, cannabinoid receptors contain seven transmembrane spanning
domains. Nowadays, there are two well-known subtypes of cannabinoid receptors
CB1 (CB1R) and CB2 (CB2R). (Fig.2)
CB1 receptors are highly expressed in neuronal cells, basal ganglia, cerebellum,
hippocampus, and cortex1, 2, 3 in according with the effects of cannabinoids on
cognition, memory, nociception and movement. Despite their principal localization
in the central system, CB1Rs are also present in the periphery, though in lower
levels, including immune and reproductive systems, liver, intestine, vascular
endothelium, and peripheral nerve synapses.
CB2 receptors are primarily located in cells involved in immune and inflammatory
responses.4 Nevertheless initially thought to be exclusively expressed in the
periphery, CB2Rs were detected in the cerebellum and the brainstem5, 6 as well, and
in microglial cells, where CB2R may play a central role in modulation of their
mobility and function both in vitro and in vivo.
Fig.2 Structure of receptors CB1 and CB2
4Besides CB1 and CB2 receptors, there are some evidences for additional CB‐like
receptors (such as GPR55,GPR18,TRPVchannels, etc.), but currently the evidence
is not considered sufficiently strong for them to be formally included in the CB
receptor family.7
1.2 Mechanism of Endocannabinoid Signaling
The mechanisms of endocannabinoid signaling in the nervous system differ
considerably from those of the classic neurotransmission systems. In the classic
model the depolarization of the pre-synaptic neuron caused by an action potential,
produce a signal that traverse the synaptic clef to bind and stimulate their cognate
receptors on the postsynaptic neuron.
Endocannabinoid signaling seems to take place via a retrograde mechanism: the
stimulation of the postsynaptic neuron, puts into action the biosynthesis of
endocannabinoids, which are then released and via transport mechanisms, not yet
known, stimulate cannabinoid receptors expressed on the presynaptic terminal.
Their stimulation involves significant changes in cellular activity mainly due to the
inhibition of adenylyl cyclase (AC) and the resulting decrease of the intracellular
cAMP levels, thereby regulating cAMP-dependent protein kinase A (PKA)
functions. Furthermore, interaction with cannabinoid receptors activates other
protein kinase, such as p38 mitogen-activated protein kinase (MAPK), focal
adhesion kinase (FAK), c-jun N-terminal kinase (JNK) and extracellular signal-
regulated kinase (ERK). CB1 receptor activation modulates calcium or potassium
conductance, properties linked to the suppression of neuronal excitability and
neurotransmitter release.
5If CB1 is activated on glutamatergic neurons, for instance, endocannabinoid
signaling will be overall inhibitory, whereas if CB1 activation takes place on
GABAergic neurons, the net result will be “disinhibitory”.
Fig 3 The MAGL modulates the 2-AG-dependent retrograde signaling in the presynaptic neuron.
Following the on demand synthesis of 2-AG, the endocannabinoid stimulates presynaptic CB1 receptor,
thus decreasing the release of other neurotransmitters. The MAGL, which is exclusively located in the
presynaptic neuron, modulates this inhibitory signal. In addition, in the postsynaptic neuron, the COX-2
appears to regulate part of the postsynaptic pool of 2-AG. On the contrary, the FAAH, which is anchored
to the membranes of intracellular compartments, does not seem to be involved in the control of 2-AG,
despite the fact that it hydrolyses this substrate very efficiently in vitro.
61.2.1 Endocannabinoids and Metabolizing Enzymes
1.2.2 Endocannabinoids Biosynthesis
Endocanabinoids are a class of neuromodulatory lipids that, differently from other
neurotransmitters, are not accumulated inside of synaptic vesicles, but are produced
“on demand” by stimulus-dependent cleavage of membrane phospholipid
precursors. Nowaday, arachidonoyl ethanolamide (anandamide, AEA) and 2-
arachidonoylglycerol (2-AG) are the best characterized.
Anandamide acts as a partial agonist at CB1 and CB2 receptors and mimics most of
the pharmacological effects produced by cannabinoid drugs in vitro and in vivo.
The mechanisms of anandamide biosynthesis in the nervous system are
incompletely understood. It is generally accepted that anandamide is generated by
calcium-dependent enzymatic transfer of arachidonic acid from the sn-1 position of
membrane phospholipids to the primary amine of phosphatidylethanolamine (PE) to
form N-arachidonoyl phosphatidylethanolamine (NArPE), followed by hydrolysis
to give anandamide.8 However, the calcium-dependent transacylase enzyme
(CDTA) that forms NArPE has still not been molecularly identified, and the route
by which NArPE is converted into anandamide remains unclear (Fig.3)
Fig. 3 Direct anandamide biosynthesis
7Multiple mechanisms and putative anandamide biosynthetic enzymes have been
suggested, including direct liberation of anandamide by NAPE-PLD, an N-acyl
phosphatidylethanolamine (NAPE)-selective phospholipase D (PLD):
 sequential O-deacylation of NArPE by the lyso(NAPE)-lipase a-b hydrolase 4
(ABHD4; Fig. 4, steps 1-2) and cleavage of the phosphodiester bond by the
glycerophosphodiesterase GDE1 (Fig. 4, step 3);
   O-deacylation of NArPE by phospholipase A2 (Fig. 4, step 1) and hydrolysis of
the phosphodiester bond by a lyso-PLD enzyme (fig. 4, step 4);
 conversion of NArPE to phospho-anandamide by a phospholipase C (PLC)-like
enzyme (Fig. 4, step 5) followed by dephosphorylation by the tyrosine phosphatase
PTPN22 or the inositol 592phosphatase SHIP (Fig. 4, step 6).
2‐arachidonoylglycerol is a full agonist at cannabinoid receptors, although less
potent than AEA, stimulates GPR55 receptors in transfected cells, acts as a
retrograde messenger on pre‐synaptic CB1R located on excitatory and inhibitory
synapses to inhibit neurotrasmitter release, and is an autocrine mediator of
post‐synaptic slow selfinhibition (SSI) of neocortical interneurons. Unlike AEA,
2‐AG does not directly activate TRPV1 or PPAR receptors but can bind to
non‐CB1/CB2 targets as suggested by the observation that the behavioral effects
induced by N‐arachidonyl maleimide (NAM), a selective MAGL inhibitor with in
vivo efficacy, are only partially reversed by the CB1 antagonist Rimonabant.
8Fig. 4 Alternative anandamide biosynthesis (8. Jacqueline L. Blankman et al. Pharmacol Rev 65:849–871,
April 2013)
2-AG is synthesized from arachidonoyl-containing diacylglycerol (DAG)
species by sn-1-specific diacylglycerol lipase-a and-b (DAGLa and DAGLb)
(Fig. 5). Characterization of DAGL(–/–) mice confirmed a primary role for
DAGLa in 2-AG formation in the brain and DAGLb in peripheral tissues, such
as the liver.9 DAG precursors are themselves synthesized from membrane
phospholipids with most evidence suggesting that the major 2-AG biosynthetic
pathway is the hydrolysis of sn-2 arachidonoyl phosphatidylinositol 4,5-
bisphosphate (PIP2) species by PLCb (Fig. 5).
Fig. 5 2-Arachidonoylglycerol biosynthesis
91.1.1. Enzymes Involved In Endocannabinoid Degradation
After being released in the synaptic cleft and completing their biological actions,
anandamide and 2-arachidonoylglycerol are degraded by a metabolizing system,
consisting of two serine hydrolase enzymes, fatty acid amide hydrolase (FAAH)
and monoacylglycerol lipase (MAGL).
FAAH  is a ~60 kDa integral membrane protein with a single N-terminal
transmembrane domain. It is both a serine hydrolase, an enzyme class employing a
nucleophilic serine for catalysis, and a member of the amidase signature enzyme
family.  Unlike most serine hydrolases, which use a histidine residue as a catalytic
base, FAAH engages a lysine for the same function, peculiarity that enables FAAH
to hydrolyze both amides and esters at equivalent rates. Structural determination of
the transmembrane-truncated rat enzyme bound to the nonselective inhibitor methyl
arachidonoylfluorophosphonate confirmed the presence of a serine-serine-lysine
(Ser241-Ser217-Lys142) catalytic triad, typical for amidase signature enzymes and
different from the serine-histidine-aspartatic acid, motif common to most serine
hydrolases. 8
FAAH is highly expressed in the mammalian brain where it is located in the
intracellular membranes of postsynaptic somata and dendrites. FAAH is the main
responsible of anandamide metabolism, through the process of hydrolysis is free
ethanolamine and arachidonic acid (Fig.6). Therefore, other metabolic pathways are
responsible for stopping anandamide signal. For example, anandamide is a substrate
of COX-2 enzymes; in fact administration of exogenous AEA to FAAH−/− mice
leads to the production of detectable levels of prostamides, suggesting that the
COX‐2 metabolic pathway becomes physiologically relevant under conditions
affecting FAAH activity or promoting COX‐2 upregulation, as it occurs in
neurodegenerative diseases or in tissue damage. In addition, lipoxygenases
(12‐LOX and 15‐LOX) and cytochrome P450, including its major brain isoform
CYP2D6 [128], convert AEA into biologically active metabolites that exert their
biological actions via cannabinoid, PPAR and TRPV1 receptors.10
10
 However, the functional role of these substances in the CNS has not been
determined.
Fig. 6 Endocannabinoid hydrolysis. In the nervous system, anandamide is degraded primarily by FAAH
MAGL is a soluble serine hydrolase associated with membranes,  that preferentially
hydrolyzes monoacylglycerols to glycerol and fatty acid (Fig.7), with highest
expression in brain, cerebellum, cortex, thalamus, and hippocampus where, like
CB1 receptors, it is primarily localized to presynaptic axon terminals. MAGL is also
localized in the liver and adipose tissue, where it was characterized as an enzyme
responsible for the last step of triglyceride catabolism. Multiple subsequent studies
have revealed MAGL as a key mediator of 2-AG degradation in the nervous
system. Although MAGL is the major responsible for its hydrolysis in intact
neurons 11-12, 2-AG can be metabolized by FAAH as well, and similary to AEA, it
is a putative substrate of COX and LOX enzymes.
Fig.7 Endocannabinoid hydrolysis. In the nervous system, in the liver and adipose  tissue
2-AG is degraded primarily by MAGL.
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Confirmation of MAGL as the primary enzime involved in 2-AG hydrolysis in
nervous system and in several peripheral tissues was achieved through different
findings: both the administration of a selective and in vivo active MAGL inhibitor,
JZL184, and the genetic disruption of MAGL activity, reduced brain 2-AG
hydrolase activity by ≃85%, dramatically elevated 2-AG levels, and provided a
select subset of cannabinoid behaviors.
Thanks to a functional proteomics approach, the 2-AG hydrolysis activity in MAGL
inhibition-insensitive brain membranes of mouse (≃15% of total activity) was
recently well-established, and attributed to the previously uncharacterized enzymes
a/b-hydrolases 6 and 12 (ABHD6 and ABHD12).8
ABHD6 is a ≃30- kDa integral membrane serine hydrolase predicted to adopt an
intracellular orientation. Murine ABHD6 expression is abundant in brain and
multiple peripheral tissues and cell types.In the mouse brain, ABHD6 is highly
expressed in cortical areas, where it is preferentially located in postsynaptic
dendrites that are often juxtaposed to presynaptic CB1 receptors.
ABHD12, instead, is a ≃45-kDa membrane glycoprotein and it is predicted to
contain a single-pass transmembrane domain and to face the extracellular/luminal
cellular space. High ABHD12 mRNA expression has been detected in mouse brain,
bladder, prostate, white adipose, macrophages, and microglia.
Despite their limited contribution to bulk 2-AG degradation, it is possible that the
different subcellular or cellular localizations occupied by ABHD6 and ABHD12
compared with MAGL, might allow each enzymes to access to distinct pools of 2-
AG in the nervous system. Indeed, ABHD6 has recently been shown to regulate 2-
AG degradation and signaling in murine primary neurons and cortical slices and
control 2-AG accumulation in the Neuro2A cell line, which lacks MAGL.
Additionally, ABHD6 inhibition in vivo produced CB1- and CB2-mediated anti-
inflammatory and neuroprotective effects in a mouse model of traumatic brain
injury. Human genetics has individuated ABHD12 as a critical regulator of
neurologic functions. For instance, loss-of-function mutations in ABHD12 cause
the human neurodegenerative disease PHARC (polyneuropathy, hearing loss,
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ataxia, retinosis pigmentosa, and cataract), although ABHD12-disruption leads to
neuronal death by dysregulation of 2-AG or an alternate mechanism remains to be
determined.8
Fig. 8 Schematic representation of 2‐AG inactivating pathways. 2‐Arachidonoylglycerol signaling is
terminated by MAGL, ABHD6 or ABHD12‐ mediated hydrolysis or by COX2 oxidation into PGH2‐G. Note
that arachidonic acid, PGH2‐EA and PGH2‐G can be further transformed into other bioactive lipids, such
as prostaglandins and endocannabinoid‐derived prostaglandins, respectively.
To sum up, endocannabinoids are recognized as a new class of lipid signals in
the CNS, which modulate excitatory and inhibitory neurotransmission and
synaptic plasticity. These new lipid signals do not exclusively bind
cannabinoid receptors, but show an important activity for their ability to
activate ionotropic and nuclear targets (TRPV1 and PPAR), as well as other
receptors non-CB1/CB2.
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2. MAGL LIKE PHARMACOLOGICAL TARGET
The metabolic activity of MAGL release arachidonic acid (AA) and glycerol, both
involved, directly or indirectly, in pathological processes such as inflammation and
carcinogenesis. These metabolites are also substrates of important pathological
pathways: arachidonic acid is precursor for the synthesis of pro-inflammatory
prostaglandins, while glycerol and other lipid substrates (released by the activity of
MAGL in adipose tissue) are sources of free fatty acids for synthesis of oncogenic
signaling lipids that promote cancer aggressiveness.
2.1 The role of MAGL in pain and inflammation
Use of Cannabis Sativa for medicinal purposes in popular cultures has been known
for several years, especially as antinociceptive, anti-asthmatic, anti-anxiety, anti-
emetic therapies; however, the side effects at psychomotor, affective and cognitive
levels restrict the use of this drug in therapy.
An interesting alternative to the use of cannabinoid receptor agonists may be
represented by the inhibition of the catabolic enzymes, fatty acid amide hydrolase
FAAH and monoacylglycerol lipase MAGL, involved in degradation of the
endogenous cannabinoids, anandamide and 2-arachidonoylglycerol respectively.
Inhibitors of endocannabinoid metabolic enzymes produce antinociceptive and anti-
inflammatory effects through a dual action : increasing endocannabinoid levels
and reducing the production of arachidonic acid.
Nowadays, it is well established that FAAH inhibitors produce antinociceptive
effects in multiple pre-clinical nociceptive assays, including neuropathic,
inﬂammatory, and acute thermal nociception. Furthermore, it was shown that an
antinociceptive effect, without the development of functional tolerance to CB1
receptors is obtained after repeated administrations of FAAH inhibitors in mice.
While the impact of selective FAAH inhibition has been well-established, selective
MAGL inhibitors have only recently been developed and the in vivo consequences
of elevating 2-AG levels have not been well-examined.. The two most potent
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MAGL inhibitors available today are JZL184 and KML29. In particular, KML29 is
known to be the most selective MAGL inhibitor, and the ﬁrst that increases 2-AG
levels, but does not possess cross-activity with FAAH, compared to JZL184, or
other serine hydrolases. It was demonstrated that this compound produced
signiﬁcant anti-allodynic and anti-edematous effects in the carrageenan model of
inﬂammatory pain and partially reversed mechanical and cold allodynia in the
chronic constriction injury (CCI) model of neuropathic pain. All these effects seem
to be mediated through distinct cannabinoid receptor mechanisms of action. For
instance, both CB1 and CB2 receptors play fundamental roles in the anti-allodynic
effects of MAGL inhibitors in the carrageenan model of inﬂammatory pain, but
only CB1 receptors are necessary for the anti-allodynic effects in the CCI
neuropathic pain model. CB2 receptor component in the anti-allodynic effects of
MAGL inhibition in the various inﬂammatory pain models could be associated to
infiltration of immune cells, which present a high CB2 expression. Differently, the
CB1 receptor component may be mediated by activation of these receptors located
supraspinally, spinally or in peripheral nociceptors.13
It is well known that the antinoceptive effect of endocannabinoids involves both
supraspinal structures (e.g. periaqueductal gray, thalamus, rostral ventromedial
medulla and amygdala), and the dorsal horn of the spinal cord. In the CNS, MAGL
is localized mainly presynaptically and is also expressed in microglia.
Endocannabinoids are produced in dorsal root ganglion cells, a primary afferent
input to spinal cord. However, anatomical localization of MAGL in the periphery is
not known.
15
 Thus, the antinociceptive effects of MAGL inhibitors in pain models involving a
strong inﬂammatory component, may involve both neuronal and non- neuronal sites
of action, within the CNS and periphery.
Fig. 10 Connecting cannabinoid and prostaglandin pathways: inhibition of MAGL (a) increased the levels of 2-
arachidonoylglycerol (2-AG) in the brain, which added through the cannabinoid receptors to decrease pain (b)
and lowers the production of arachidonic acid to decrease levels of inflammatory prostaglandins and blunt
inflammation in the brain (c)
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2.1.1 Relation MAGL-Cyclooxygenase
The positive effects of selective MAGL inhibitors such as antinociceptive and
gastroprotective effect, are due to a strong correlation between this serine hydrolase
and cyclooxygenase enzymes (COX). The reason for this connection, is related to
FAAH and MAGL enzymatic activity itself, since they hydrolyze their respective
substrates, anandamide and 2-AG, producing arachidonic acid, which is substrate of
COX emzymes. (Fig.11)
Fig.11 Endocannabinoid hydrolysis. In the nervous system, anandamide and 2-AG are degraded primarily by
FAAH and MAGL, respectly.
Cyclooxygenase (COX), officially known as prostaglandin-endoperoxide
synthase (PTGS). This enzyme exists in two isoforms COX-1 and COX-2 are of
similar molecular weight, approximately 70 and 72 kDa, respectively, and having
65% amino acid sequence homology and near-identical catalytic sites. The most
significant difference between the isoenzymes, which allows for selective
inhibition, is the substitution of isoleucine at position 523 in COX-
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1 with valine in COX-2. The smaller Val523 residue in COX-2 allows access to
a hydrophobic side-pocket in the enzyme (which Ile523 sterically hinders).
COX catalyzes the conversion of arachidonic acid (or other 20 carbon fatty acids) to
prostaglandin (PG) G2 and PGH2. PGH2 is subsequently converted to a variety of
eicosanoids that include PGE2, PGD2, PGF2α, PGI2, and thromboxane (TX) A2
(Fig.12) .  Prostaglandins are found  in a wide variety of human tissues, they are
involved in diverse functions, including platelet aggregation; the maintenance of
electrolyte balance; control the tone of vascular smooth muscle and bronchial;
uterine contraction during childbirth. Very important is the action of prostaglandins
on the mechanism of inflammation. They in fact determine the amplitude and
duration of the inflammatory reaction with local regulation of blood circulation, the
control of vascular permeability and the regulation of macrophage and leukocyte
chemotaxis. Because of their function, they are the pharmacological target of
NSAIDs (non-steroidal anti-inflammatory drugs). Furthermore, prostaglandins exert
a cytoprotective of the gastric mucosa to reduce the production of hydrochloric acid
in favor of the secretion of mucus.
Fig.12  COX produce prostaglandin H2 (PGH2) from arachidonic acid (AA) in two consecutive
chemical reactions. The PGH2 is then converted to other prostanoids (bottom) tissue-specific
enzyme called isomerase. In the first step of the reaction, two moles of oxygen are added to
arachidonic acid to form the intermediate "prostaglandin G2" (PGG2), in the reaction of
cicloossigenaazione proper. This first reaction is followed by peroxidase that occurs in two different
positions of the enzyme
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COX-1 has been localized in nearly all tissues under basal conditions , it’s a
Constitutive isoform (Its concentration in the body remain stable). COX-1 is
expressed in the vasculature, glomeruli, and collecting ducts of the kidney, and it
appears to be important in producing the vasodilating PGs, which maintain renal
plasma flow and glomerular filtration rate during conditions of systemic
vasoconstriction. One important site of COX-1 function is the blood platelet, where
the enzyme is responsible for providing precursors for thromboxane synthesis,
Creates prostaglandins used for basic house keeping throughout body.
COX-2 is an isoform inductive, (normally not in present in the cells), is stimulated
due to of an inflammatory response; the presence of proinflammatory cytokines
leads COX-2 to produce prostaglandins in support of inflammation and to promote
the pain transmission.
Prostaglandin E2 (PGE2) is a crucial mediator of inflammatory pain sensitization
and it’s the most effective in modulating the integrity of the gastrointestinal mucosa
and in carrying out various functions of the gastrointestinal tract . Prostaglandin E2
is produced in response to inflammation both in peripheral inflamed tissues and in
the spinal cord12.
 arachidonic acid transformed into the prostaglandin precursors Prostaglandin G2
and Prostaglandin H2 by constitutively expressed Cyclooxygenase-1 ( COX-1 ) or
inducible Cyclooxygenase-2 ( COX-2 ). Prostaglandin H2 is further converted by
Prostaglandin E synthase ( PGES ) or Prostaglandin E synthase 2 ( PGES2 ) into
Prostaglandin E213-14. To act as signaling molecules, prostaglandins must be
released from the cells where they are synthesized. Prostaglandin E2 can diffuse
passively from the cell and/or can be actively transported by Solute carrier organic
anion transporter family member 2A1 ( SLC21A2 )15 .
Prostaglandin E2 exerts its function by acting on a group of G-protein-coupled
receptors. There are four subtypes of Prostaglandin E2 receptors (also designated as
subtype EP1, EP2, EP3 and EP4), PGE2R1, PGE2R2, PGE2R3 and PGE2R419.
PGE2R2, PGE2R3 (gamma isoform) and PGE2R4 couple to G-protein alpha-s
resulting in stimulation of Adenylate cyclase, increase Cyclic 3,5-adenosine
19
monophosphate ( cAMP ) levels and subsequent activation of cAMP-dependent
protein kinase A ( PKA)16.
Prostaglandin E2 signaling underlies alterations in synaptic transmission within the
spinal cord dorsal horn that plays a key role in the development of inflammatory
pain. Peripheral nociceptors make synaptic contacts with local excitatory and
inhibitory interneurons and central projection neurons, which convey nociceptive
information to higher central nervous system areas. The spinal cord dorsal horn is
the first site of synaptic integration in the pain pathway. Prostaglandin E2 signaling
can modulate the neurotransmission and increasing the responsiveness of peripheral
nociceptors that generate excitatory glutamatergic transmission.
The mechanisms underlying the actions of PGE2 are closely related to the
inhibition of the contraction of the stomach (EP1), the stimulation of duodenal
HCO3-secretion (EP3/EP4), inhibition of small intestinal contraction (EP4), the
stimulation of mucus secretion (EP3/EP4) and, finally, to the down-regulation of
cytokine secretion in the colon (EP4). Another property of the prostaglandin E-type
is to promote healing in cases of gastric and intestinal lesions through the activation
of EP4 receptors. Finally, it was found that PGE2 also show an interesting action
consists in inducing angiogenesis in different models, the expression of VEGF
(Vascular endothelial growth factor), suggesting the participation of the latter in
inflammatory processes.
We can deduce, that with specific inhibitors for MAGL and FAAH it can modulate
pain transmission and inflammation by acting indirectly on COX with further
benefits. These benefits have been observed with the use KML29, that produced a
dose-dependent CB1 receptor mediated gastroprotective effect in the NSAID-
induced gastric hemorrhage model. Thus, MAGL inhibition may be an effective
strategy for the prevention of NSAID- induced gastric ulcers.11 Nomura et al. (2001)
demonstrated that hydrolysis of 2-AG by MAGL represents an important pathway
of formation of arachidonic acid in the brain. Thus, MAGL inhibition causes a
reduction of brain levels of AA, and a subsequent decrease of prostaglandins and
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pro-inﬂammatory cytokines following inﬂammatory insults. Therefore, it is
necessary to evaluate the possibility that decreased prostaglandin synthesis, as a
consequence of decreased availability of substrate for their production (i.e. AA),
may contribute to the antinociceptive effects of MAGL inhibitors. In addition,
KML29 produced a dose-dependent CB1 receptor mediated gastroprotective effect
in the NSAID-induced gastric hemorrhage model. Thus, MAGL inhibition may be
an effective strategy for the prevention of NSAID- induced gastric ulcers.11
Finally, these studies showed that the inhibitor KML29 not provide cannabimimetic
side effects, such as catalepsy, hypothermia, or hypomotility, neither at high doses.
At the end MAGL inhibition produces beneﬁcial antinociceptive and
gastroprotective effects, without unwanted cannabimimetic side effects similar to
those produced by THC and other effects produced by NSAID. Everything,
suggests that the MAGL inhibitors such as KML29 and JZL184 is a new
therapeutic strategy in the treatment of inflammation and neurophatic pain, with a
significant likelihood of reducing cannabimimetic side effects.11
21
2.2 The Role of MAGL in Neurodegenerative Diseases
At the current state of knowledge, inflammation is a feature of many neurological
disorders, including chronic pain, traumatic brain injury, neurodegenerative
diseases such as Parkinson's and Alzheimer's disease4-6. The inflammatory process
in the nervous system, is due to the activity of COX (COX-1 and COX-2), localized
in neurons and glial cells. The cyclooxygenase mediate the conversion of
arachidonic acid to prostaglandins, which are responsible of maintaining of the
inflammatory process.
Phospholipase A2 (PLA2) enzymes, and cytosolic PLA2 (cPLA2 or Pla2g4a) in
particular, have been viewed as the principal source of arachidonic acid (AA) for
COX-mediated prostaglandin production9; however, cPLA2-deficient mice have
unaltered AA levels in brain10. These findings, together with results that genetic or
pharmacological inactivation of monoacylglycerol lipase (MAGL, Mgll) in mice
results in significant reductions in brain AA12-13, highlights the that there are
different mechanisms from the PLA2, which regulate the production of
prostaglandins in the nervous system. Consistent
with previous investigations, we found that mice deficient in the gene that encodes
MAGL (Mgll–/– mice) or mice treated with the MAGLselective inhibitor JZL184
showed loss of MAGL activity 12-13, but not other brain serine hydrolase activities,
and had elevated brain levels of 2-AG and corresponding reductions in AA16.
MAGL has been studied mostly for its role in hydrolyzing the endocannabinoid 2-
arachidonoylglycerol (2-AG)12, 15, 16 . These results indicate that the principal
metabolic effects of disrupting MAGL in the brain are elevations in substrate
MAGs, including 2-AG, and reductions in the product AA and downstream AA
derived eicosanoids.
In the mouse brain, we found that IL-13Rα1 was expressed in the dopaminergic
(DA) neurons of the substantia nigra pars compacta, which are preferentially lost in
human Parkinson’s disease 20.
During a study mice were systemically administered the proinflammatory agent
lipopolysaccharide (LPS), LPS treatment produced a robust, time-dependent
increase in brain eicosanoids , and these changes were markedly blunted in mice
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treated with JZL184 and in Mgll–/– mice. It is interesting the finding that the
impairment in brain eicosanoid production in MAGL-deficient animals was not
reversed by CB1 or CB2 receptor antagonists or in mice lacking of CB1R and CB2R,
which demonstrates that this metabolic effect is a direct consequence of reductions
in AA rather than an indirect consequence of enhanced endocannabinoid signaling.
  It has been noted that LPS treatment did not alter brain AA levels, despite causing
elevations in prostaglandins. This finding could be explained in the context of
previous reports showing that LPS induces COX1 expression in the brain (19). A
model thus emerges where LPS-induced COX1 shunts a small proportion of the
high bulk levels of AA toward prostaglandins, which are found at much lower
levels in brain. By controlling the quantity of AA available to LPSinduced COX1,
MAGL exerts a crucial control over brain prostaglandin production in both basal
and neuroinflammatory states.
It is known that MAGL and cPLA2 contribute to the AA pools for
neuroinflammatory prostaglandins at cerebral level, but depth studies have shown a
different activity at the peripheral level. These findings reveal a clear anatomical
segregation for the enzymatic pathways that supply the AA precursor of
proinflammatory prostaglandins, and further, they suggest that MAGL inactivation
may avoid some of the major adverse pharmacological effects of COX inhibitors
such as gastrointestinal bleeding . Consistent with our finding, JZL184 does not
cause the gastric hemorrhaging that is observed with COX1 or dual COX
inhibitors7.
These findings identify MAGL as a distinct metabolic node that couples
endocannabinoid to prostaglandin signaling networks in the nervous system and
suggest that inhibition of this enzyme may be an innovative way to suppress the
pro-inflammatory cascades that underlie neurodegenerative disorders.
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2.3 The Role of MAGL in Cancer and Cancer-Related
Symptoms
Cancer cells display alterations in metabolism that provide a biochemical
foundation for tumors to progress in their etiology; these changes include aerobic
glycolysis, glutamine dependent anaplerosis , and de novo lipid biosynthesis21. All
these metabolic pathways appears to be crucial for the transformation of cells from
a noncancerous to a cancerous state; however, it is not know about such the
metabolic pathways that confer the aggressive properties observed in malignant
cancers, such as high migratory and invasive activity.  Detailed studies have
confirmed that heightened de novo lipid biosynthesis, or the development of a
‘‘lipogenic’’ phenotype, has been posited to play a major role in cancer. It has been
observedelevated levels of fatty acid synthase (FAS), the enzyme responsible for
fatty acid biosynthesis from acetate and malonyl CoA, are correlated with poor
prognosis in breast cancer patients22. FAS may support cancer growth, at least in
part, by providing metabolic substrates for energy production (via fatty acid
oxidation)23. The lipid biochemistry, is not limited only to provide energy to cancer
cells, but plays other critical roles in sustaining the malignancy of cancer cells such
as:
I. The generation of building blocks for newly synthesized membranes to
accommodate high rates of proliferation24 .
II. The composition and regulation of membrane structures that coordinate
signal transduction and motility, such as lipid rafts, invadopodia, blebs.25 The
biosynthesis of an array of protumorigenic lipid-signaling molecules. Examples of
lipid messengers that contribute to cancer include : phosphatidylinositol-3,4,5-
trisphosphate that activates protein kinase B/Akt to promote cell proliferation and
survival26. Lysophosphatidic acid (LPA), which signals through a family of G
protein-coupledreceptors to stimulate cancer aggressiveness27. Prostaglandins
formed by cyclooxygenases, which support migration and tumor-host interactions28.
So lipogenesis may contribute to the development of cancer, but it is necessary to
consider that the newly synthesized fatty acids are immediately stored in special
warehouses. Therefore, the use of each of the aforementioned models necessitates
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that cancer cells also possess a complementary ‘‘lipolytic’’ pathway to liberate
stored fatty acids for metabolic and signaling purposes.  Recently it was discovered
that monoacylglycerol lipase (MAGL) is elevated in aggressive cancer cells and
primary tumors, where this metabolic enzyme through hydrolysis of
monoacylglycerols (MAGs), controls free fatty acid (FFA) levels in cancer cells.
The resulting MAGL-FFA pathway feeds into a diverse lipid network enriched in
protumorigenic signaling molecules and promotes migration, survival, and in vivo
tumor growth. To support of this hypothesis, it was followed a treatment with the
FAS inhibitor C75  did not reduce FFA levels in cancer cells .Besides aggressive
and nonaggressive cancer cells exhibited similar levels of FAS, indicating that
lipogenesis in the absence
of paired lipolysis may be insufficient to confer high levels of malignancy. It is
concluded that  aggressive cancer cells do indeed acquire the ability to liberate
FFAs from neutral lipid stores as a consequence of heightened expression of
MAGL. MAGL and its FFA products were found to be elevated in aggressive
human cancer cell lines from multiple tissues of origin, as well as in high-grade
primary human ovarian tumors. Further evidence in support of this premise
originates from gene expression profiling studies, which have identified increased
levels of MAGL in primary human ductal breast tumors compared to less malignant
medullary breast tumors 29.
Because direct cannabinoid receptor agonists have been shown to impair cell
growth, tumorigenicity, and metastasis, is possible that, at least for certain cancer
types, MAGL could also support tumorigenicity by limiting the negative impact of
endocannabinoids on cancer cell growth.
Interestingly, after what has been said, blockade of MAGL by JZL184 produced
significant elevations in the levels of several MAGs, including 2-AG, in each of the
aggressive cancer cell lines; however, MAGL inhibition also caused significant
reductions in the levels of  FFAs in aggressive cancer cells. Indeed that cannabinoid
receptor agonists exhibit anti-cancer proprieties through inducing apoptosis in vitro
and angiogenesis and metastasis in vivo. Beyond their direct effects against cancer,
cannabinoid have been clinically used to relieve chemotherapy side effects, such as
nausea, pain, and lack of appetite.
25
Consistent with these clinical benefits of direct cannabinoid agonists, MAGL
inhibition exerts a double effect in anticancer therapy :
 Reducing the malignancy of aggressive human cancer cells, reducing levels
FFAs and increasing levels of  2-AG.
 Alleviating cancer-associated symptoms such as anti-hyperalgesic effect via
a CB2-depent manner and nausea.
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3 MONOACYLGLYCEROL LIPASE (MAGL)
3.1 MAGL: Structure and Most Important Residues 9
Monoacylglycerol lipase (MAGL) hydrolyzes 2-AG thus terminating its biological
actions30, and works consecutively with hormone- sensitive lipase (HSL) thus
mobilizing fatty acids from the triglyceride stores of adipocytes. MAGL was
originally isolated and cloned from adipose tissue, where it was characterized as an
enzyme responsible for the last step of triglyceride catabolism23. Since its first
identification in the adipose tissue, MAGL localization has been extended to many
other tissues, and it is now well-estabilished that this serine hydrolase constitutes an
ubiquitously expressed enzyme. In rat, high levels of mRNA MAGL were found in
adipose tissue, kidney and testis. High levels of MAGL expression awere also
individuated in other organs, such as adrenal gland, brain, heart, lung, skeletal
muscle, liver, ovary and spleen (in descending order of MAGL mRNA
abundance)31. In the brain, MAGL transcript is also present ubiquitously (cortex,
hippocampus, cerebellum, thalamus, striatum), despite lower levels of mRNA were
found in brain stem and hypothalamus32.  MAGL has a molecular weight of ~33
kDa, and exhibits a high degree of amino acid sequence homology among human,
mouse, and rat.17 , 18 , 31 . MAGL architecture presents the hallmark of the α/β
hydrolases superfamily. The central β‐sheet, constituted of seven parallel and one
antiparallel strands, is surrounded by six α-helices. Moreover, a flexible cap domain
covers the structurally conserved β‐sheet and a lid domain guards the entrance of a
relatively large, occluded hydrophobic tunnel (approx. 25 Å in length and approx. 8
Å in width)., The active site is buried at the bottom of the tunnel16 (Fig. 13 B). The
cap domain seems to act as a lid; allowing the enzyme to unveil its otherwise
unreachable hydrophobic active sites when  the protein come into contact with lipid
droplets. This process has been termed “interfacial activation”, and thereby allows
the enzyme to exist in two main conformational states, a closed and an open form
(authors suggested the hypothesis that the enzyme naturally adopts an open
conformation in solution [C. Eydoux, S. Spinelli, T. L. Davis, J. R. Walker, A.
Seitova, S. Dhe-Paganon,De Caro, C. Cambillau, F. Carri_re, Biochemistry 2008,
47, 9553– 9564.]
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Both catalytic site entries face the same direction and are thus properly oriented to
interact with the membrane in order to recruit the substrates. However, as the
central core of the α/β hydrolase family members is highly conserved, the model
offered first insights into the MAGL active site with the catalytic triad: serine 122
(S122), aspartic acid 239 (D239) and histidine 269 (H269), previously identified
through  mutagenesis studies (Fig. 13). This model also suggested that two cysteine
residues (C208 and C242) were located within a close distance from the active site
and  both these cysteines can be involved in binding processes.
Fig.13 Overall structure of hMAGL. A) MAGL asymmetric unit. a4 helix is colored magenta.
Membrane representation is a palmitoyloleoylphosphatidylethanolamine bilayer minimized using
molecular dynamics simulation.[47] B) Left: Side view of a MAGL monomer, with catalytic triad
represented as sticks, and cap domain colored magenta. Right: Top view (908 rotation) of the same
MAGL subunit.
Site‐directed mutagenesis studies have provided experimental support for these
predictions.16
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3.2 Binding of the Natural Substrate
The first structural basis for rational drug design is the explanation of the MAGL
structure, in order to highlight some key structural features of the active site. In this
regard 2-AG has been docked in MAGL, simulating the tetrahedral intermediate
state, covalently bound to Ser122 (Fig 14). This reveals a cavity able to
accommodate the long and flexible lipid chain of the substrates. This cavity
becomes wider moving away from the catalytic triad (Ser122, Asp239 and His269)
environment.
Fig.14 Docking of 2-AG in the active site of MAGL. The natural substrate is bound in the tetrahedral intermediate
state to Ser122. The four first conformations found by using Gold software are represented using different colours.
A) Acyl-binding and B) alcohol-binding sites are highlighted, as well as C) the glycerol exit channel. Side chains of
residues interacting with the 2-AG acyl moiety or lining the hydrophilic cavity are represented as sticks. The
interactions inthe oxyanion hole are represented with dashed lines. The a4 helix is also indicated by arrows.
Several hydrophobic residues cover the channel leading from the surface to the
nucleophilic serine. Indeed, Leu148, Ala164, Leu176, Ile179, Leu205, Val207,
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Ile211, Leu213, Leu214, VaL217 and Leu241 side chains are properly located to
interact with the arachidonoyl moiety of 2-AG, and mediate the MAGL substrate
specificity for lipid substrates.(Fig.13)
The near of the catalytic triad presents a more hydrophilic character than the
channel pointing towards the enzyme surface. Besides the backbone NH from
Met123 and Ala51, which form the “oxyanion hole”, the Tyr58 hydroxyl group, the
NH from the His121 and His272 side chains, the guanidinium from Arg57, the
carboxylate from Glu53, and the backbone carbonyl from Ala51 delimit a polar
cavity that accommodates the polar glycerol head group of 2-AG. In this pocket a
molecule of glycerol was found, thus confirming the proposing binding mode of 2-
AG. A positive electron density feature was apparent in the proximity of the
oxyanion hole at the end of the structure-refinement process. This was located at the
entry of a polar cavity and precisely at the same place of the glycerol moiety in 2-
AG docking results (Fig.15). The glycerol alcohol moiety interacts with the Ala51
carbonyl group, Tyr194 alcohol and Glu53 carboxylate. The His121 lateral chain
and a conserved water molecule inside the cavity are located close to the alcohol-
binding pocket and therefore might also interact with the glycerol function and
participate to the MAGL selectivity for monoacylglycerols.
Fig. 15 Electron density in MAGL active site. A glycerol molecule is bound in the alcohol-binding pocket
(Chembiochem. 2010 Jan 25;11(2):218-27 )
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3.3 MAGL Catalytic Mechanism
MAGL operates according to the mechanism of the lipolytic enzymes, which
involves two stages:
1) Stage bonding , which involves the interaction of the enzyme with the lipid-
water interface.
2) The substrate enters the catalytic site, where the hydrolysis of the ester bond
occurs as a result of the nucleophilic attack of the catalytic serine  activated
hydroxyl group on the substrate activated carbonyl carbon by an universal acid-base
mechanism. The initial step of the mechanism is the protonation of the His269 in
the active site from the serine residue. Histidine protonation is stabilized by the
negative charge associated with Asp239, the third residue of the MAGL catalytic
triad, which lies in a hydrophobic environment. In this manner, the catalytic Ser122
becomes a strong nucleophile and attacks the carbonyl carbon of the substrate with
consequent formation of a tetrahedral intermediate that is stabilized by the oxyanion
hole; this is responsible for the activation of the carbonyl group of the substrate.
When the tetrahedral intermediate (His269, Ser122, Asp239) is formed, the
mechanism of action of the enzyme proceeds, with the acylation of the serine and
the elimination of the leaving group. (Fig 16). The enzyme can return to the active
form only when, a water molecule attacks the active site, favoring the deacylation
of serine and allowing MAGL, to repeat the hydrolytic process.
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Fig. 16 Schematic representation of the general catalytic mechanism of serine hydrolases
4. MAGL  INHIBITORS
Monoacylglycerol lipase (MAGL) is one of the key enzymes of the
endocannabinoid system (ECS). Furthermore, MAGL hydrolyzing and degrading
the endocannabinoid 2-arachidonoylglycerol (2-AG), is able to release  the
arachidonic acid (AA), which is the major precursor for the synthesis of pro-
inflammatory eicosanoids in specific tissues, such as the brain, liver and lung
(Nomura et al 2011b). In aggressive cancer cells, MAGL supplies the pool of free
fatty acids for production of protumorigenic signalling lipids.
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Consequently, inhibition of MAGL, which results in increased 2-AG levels, leads to
several beneficial therapeutic effects, such as  attenuation of pain, anxiety, nausea,
inflammation, neurodegeneration, precipitated opioid withdrawal responses, and
cancer pathogenicity. Taken together, these data suggest that MAGL is a potential
target for the development of new drugs.
4.1 General Serine Hydrolase Inhibitors
Selective pharmacological tools to disrupt MAGL activity MAGL in vivo have
become available only within the last few years. The activity  of this enzyme is
sensitive to general serine hydrolase inhibitors such as methyl
arachidonoylfluorophosphonate, PMSF, arachidonoyl trifluoromethylketone, and
hexadecysulfonylfluoride (Dinh et al., 2002; Saario et al.,2004) (Tab.1). However,
these compounds are not selective for MAGL, but they present cross-activity with
FAAH. Therefore, because of their similarity in  the enzymatic mechanism and in
the substrate structure, the searching for the structural essential characteristics to
inhibit selectively MAGL over FAAH was necessary.
Tab. 1: Inhibition of 2-AG and AEA hydrolysis by general serine hydrolase inhibitors
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After, a new study demonstrated that same  sulfhydryl-specific agents, including p-
chloromercuribenzoic acid, mercury chloride, and N-ethylymaleimide, indicating
the presence of a critical free cysteine residue (Tornqvist and Belfrage, 1976;
Sakurada and Noma, 1981; Saario et al., 2005).
All the compounds able to inhibit MAGL can be differentiated into reversible and
not reversible in terms of type of interaction with the enzyme.
The first generation of functional MAGL inhibitors, more or less selective,
includes:
4.1.1 The carbamate compound URB602.
It was reported as a selective MAGL inhibitor with relatively low potency; this
compound produced a modest (2-fold) increase in 2-AG concentration, but not in
anandamide concentration, and enhanced stress-induced analgesia (Hohmann et al.,
2005). Because of the lack of power, several difficulties in the in vivo
administration were observed, also followed by the emerging controversies about its
selectivity against FAAH in vitro. (Muccioli et al., 2007; Vandevoorde et al., 2007).
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4.1.2 Inhibitors Inspired by the Endogenous Substrate
2- AGAnalogues
Within the structure of the endocannabinoid 2‐AG it is possible to individuate
three main parts susceptible to modifications: fatty acid chain, linker and glycerol
moiety (Fig. 17).
Fig. 17 2‐AG structure: points of structural modification
Based on this, the ability of a series of analogues of 2-AG (Table 2) to inhibit
cytosolic MAGL was examined.
The experimental data show that both isomers 2-AG and 1-AG are equipotent in
disrupting MAGL activity (IC50 = 13 and 17 µM, respectively). 9
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Tab. 2 Inhibition of MAGL and FAAH by 2-AG analogues
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Among the derivatives inspired by the 2-AG, stand out for their activity:
1. N-Arachidonoyl maleimide NAM: It is an irreversible MAGL inhibitor
that was found to decrease MAGL hydrolyzing activity in rat cerebellar membranes
by 90% (Saario et al., 2005). Maleimide group is a general thiolreactive electrophile
that reacts with cysteine-containing proteins in vivo. Iits use in physiologic studies
was limited because of the cross-activity with FAAH (Blankman et al., 2007).
N
O
O
NAM
2. The tetrahydrolipostatin derivative OMDM169. It was shown to inhibit
MAGL and pancreatic lipase with approximately 10-fold selectivity over FAAH.
and it shown a nociceptive effect in mice by increasing 2-AG levels. Its action is
limited to the peripheral level, since it has not been found any inhibitory activity in
the brain. (Bisogno et al., 2009)
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4.3. De novo inhibitors
4.3.1 Carbamate function
O-Aryl carbamates., Recently (2009) a novel MAGL inhibitor, the piperidine
carbamate JZL184, was reported in order to investigate  about the role of MAGL in
2-AG signaling termination, and the potential use of MAGL inhibitors for  the
treatment of nervous system disorders, such as pain, anxiety, addiction, and nausea
(Minkkilä et al, 2010. Petrosino and Di Marzo, 2010). JZL184 is a carbamate
piperidine, which selectively inhibit MAGL in vivo, through irreversible
carbamoylation of the catalytic serine of the enzyme. It was demonstrated that
JZL184 presents remarkable selectivity for MAGL against other serine hydrolase in
the brain.(Long et al. , 2009a , 2010) Consistent with previous findings (Saario et
al., 2005; Blankman et al., 2007), It is able to inhibit MAGL decreasing 2-AG
hydrolysis in mouse brain membranes by 85% (Long et al.,2009a). A single
injection of JZL184 (16 mg/kg i.p., PEG vehicle) inhibited MAGL in the mouse
brain for up to 24 hours and produced maximally elevated brain 2-AG levels (8-
fold) for at least 8 hours without altering anandamide levels.However JZL184
showed, at cerebral level, a partial activity against FAAH when administered at
high doses or chronically, resulting in a modest increase of anandamide. Whereas at
the peripheral level, it has been observed, that JZL184 is able to inhibit, like other
carbamate derivatives, different enzymes of the endocannabinoid system. (Long et
al., 2009b).
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Despite this, JZL184 is the first example of how the carbamate is a key moiety for
the design of new potent and selective inhibitors.
4.3.2 FLUORO DERIVATE
1. O-Hexafluorisopropyl Carbamates, for example, KML29. Recently
discovered, they are next-generation MAGL inhibitors based on an O-
hexafluoroisopropyl carbamate scaffold. The O - esafluoroisopropilico, has
maintained the same inhibitory activity against MAGL but improved the selectivity
of FAAH and ECS enzymes both in vitro and in vivo. KML29 dose dependently
inhibited MAGL and dramatically elevated brain 2-AG levels without disrupting
FAAH activity. KML29 exhibited complete selectivity against FAAH even after
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chronic administration. KML29 administered to rats, inhibited 90% username
enzymes MAGL with a rise equal to 10 times the levels of 2-AG without affecting
the levels of anandamide. Therefore, represents a versatile inhibitor that can be used
to investigate MAGL function in human cell and rodent models under both acute
and chronic dosing regimens. (Bartsch et al.2011).
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2. Derivate triazolocarboxamide SAR629, it shows a nanomolar activity
range, and its mechanism of inhibition mimics the pathway of 2‐AG MAGL-
mediated hydrolysis by making a relatively stable carbamate adduct with the
catalytic serine instead of the relatively labile ester adduct.
F
F
N N
O
N
N
N
SAR629
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Fig. 18 a) hydrolysis of 2‐AG by MAGL. b) hydrolysis of SAR 629 by MAGL (J. Mol. Biol. (2010) 396,
663–673)
In the analysis of model in which SAR629 and MAGL bound covalently, the
compound adopts a Y shape with its two fluorophenyl moieties pointing toward
opposite directions and perpendicular to each other. (Fig.19)
Fig. 19 Pharmacophoric model of SAR629 and JZL184. (Dark green elements depict flat and hydrophobic
pharmacophoric points, whereas the orange element depicts a polar pharmacophore. Ar, aromatic) (J. Mol.
Biol. (2010) 396, 663–673)
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These moieties are perpendicular to the piperidine linker that adopts a chair
conformation. In addition to the covalent bond with Ser122, SAR629 interacts with
MAGL essentially by hydrophobic interactions and few polar interactions.
Water‐mediated interactions occur between the inhibitor nitrogen piperazine or
oxygen atoms of its carbamate function and His269 side‐chain or Ala61
main‐chain carbonyl oxygen.(Fig20)
Fig.20 A) Docking study of SAR629 into the active site of the enzyme, B) van der Waals interactions of the
piperazine moiety (J. Mol. Biol. (2010) 396, 663–673)
The role of the piperazine is to orient the other moieties toward pharmacophoric
points, and it could probably be replaced by other substituents.17
The reported MAGL inhibitor JZL184 has a chemical structure very close to that of
SAR629 (Fig. 20).
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 Its mechanism of inhibition and its mode of recognition should be similar (Fig. 20//
Fig 21).17
Fig.21 Hydrolysis of JZLK184 by MAGL
4.3.3 Inhibitors Targeting the Essential Sulfhydril
Group of MAGL
The presence of some thiol groups close to the catalytic site of the enzyme led to
the design of MAGL inhibitors. A compound already known, the Disulfiram, used
in the past for treatment against alcoholism, has recently been discovered to inhibit
MAGL with micromolar affinity. The development of a series of MAGL inhibitors
based on this template. The most potent representative, bis(4-methyl-1-
piperazinylthiocarbonyl) disulfide, displayed an IC50 of 110 nM on the pure
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enzyme, and a more than 1000 selectivity ratio for MAGL compared to FAAH.
(Kapanda, C. N.; Muccioli, G. G.; Labar, G.; Poupaert, J. H.; Lambert, D. M.
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride
lipase inhibitors. J. Med. Chem., 2009, 52, 7310-4.)
4.3.4 Organophosphoric (OP) Derivatives as MAGL
Inhibitors
Inhibitors have been developed with equivalent affinity and activity of MAGL and
FAAH in order to develop the same effects promoted by exogenous cannabinoids.
To this category belong the Organophosphoric (OP) Derivatives (general structure
Fig.22)
Fig. 22 General structure of OP derivates
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.One of the most representative compounds of this class of derivatives is UP101
which showed, as we can see from table 6, a high inhibition activity of the ECS
enzyme but not selectivity towards MAGL.
Tab. 3 Inhibition activity of UP101
An other OP derivative which did not showed high selectivity for MAGL is IDFP
(Isopropyldodecylfluorophosphonate), was found to be a potent inhibitor of both
FAAH and MAGL (IC50 values of 3 and 0.8 nM, respectively) as well as many
additional serine hydrolases, including the alternate 2-AG hydrolase ABHD6,
neuropathy target esterase, and the ether-lipid metabolic enzyme KIAA1363
(Nomura et al., 2008a). Treatment of mice with IDFP caused dramatic elevations in
brain endocannabinoid levels (;10-fold); the side effects observed in mice treated
with the following compound have been manifold: hypothermia, catalepsy,
hypomotility as well as death (by a CB1 - independent mechanism).
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INTRODUCTION TO THE
EXPERIMENTAL PART
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Monoacylglycerol lipase (MAGL) is a membrane-associated cytosolic serine
hydrolase with the highest expression levels in the brain, white adipose tissue and
liver. MAGL catalyses the hydrolysis of monoacylglycerols into fatty acids and
glycerol and in particular the endocannabinoid 2-arachidonoylglycerol (2-AG) is
one of its main substrates The lipid messenger 2-AG is synthesized by
phospholipase C (PLC)-mediated cleavage of membrane phospholipids, resulting in
the release of diacylglycerol (DAG) that is then hydrolysed by diacylglycerol lipase
(DAGL) (fig. 23).
Fig.24 2-arachidonoylglycerol biosynthesis
2-AG acts primarily by binding to both cannabinoid G protein-coupled receptors
CB1R and CB2R, and it is either synthesized on demand or likely associated to
binding proteins in spatially separated pools (fig.24).
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Fig. 24 Schematic of retrograde endocannabinoid signaling in the nervous system (Pharmacol Rev 65:849–
871, April 2013)
In the brain, MAGL is responsible for about 80% of the hydrolysis of 2-AG while
the remaining 20% arises mainly from the activity of other two serine hydrolases,
α,β-hydrolase-6 (ABHD-6) and -12 (ABHD-12). The pharmacological inhibition of
MAGL activity in vivo leads to a strong accumulation of 2-AG, in particular in the
brain which triggers a higher activation of CB1R and CB2R resulting in analgesic,
anxiolytic, antidepressant, sleep-enhancing and anti-inflammatory effects. Recently,
it has been shown that in some tissues, such as brain, liver and lung, 2-AG acts as a
precursor for the arachidonic acid production. Arachidonic acid is mainly
oxygenated by cyclooxygenase-2 to generate pro-inflammatory eicosanoids such as
prostaglandin-E2 and –D2. Therefore, the analgesic and anti-inflammatory effects
induced by MAGL inhibition can be dependent on two underlying mechanisms: the
first by directly increasing 2-AG levels and the second, by lowering the arachidonic
acid formation as previously described in brain (figure 25) Thus, MAGL could
represent the link between two lipids signalling pathways: the endocannabinoid and
the eicosanoid systems. For these reasons, the modulation of MAGL activity can
lead to several beneficial effects through either enhancing the tone of the
endocannabinoid system or lowering eicosanoids production. Furthermore in
cancer, MAGL plays a distinct role in controlling global FFAs (free fatty acid)
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levels that serve as the building blocks for synthesis of pro-tumorigenic signaling
lipids such as PGE2 and lysophosphatidic acid (LPA) (figure 25).
Fig. 25 Lipid signaling pathways coordinately regulated by MAGL.
Therefore, MAGL inhibitors may represent an attractive therapeutic approach for
the treatment of pain, inflammation, anxiety, neurodegeneration, cancer and other
disorders. Moreover, regarded the anti-inflammatory activity, because MAGL
inhibitors do not exert control over arachidonic acid and prostaglandin pathways in
the gastrointestinal system, they also do not induce the gastrointestinal bleeding
associated with the use of dual COX1/COX2 inhibitors.
For all these reasons, recently MAGL has attracted much attention as an interesting
therapeutic target for the development of new drugs. Several studies, have led to the
synthesis of compounds able to inhibit MAGL catalytic activity. An important
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group of inhibitors was inspired by the endogenous substrate 2-AG, thus several 1-
AG derivatives were studied. . Furthermore, since mechanistically MAGL is a
serine hydrolase, a wide group of inhibitors is represented by compound able to
bind in either a reversible or an irreversible covalent manner to the nucleophilic
serine, such as compounds with a carbamate (JZL184) and a urea (SAR629) as
functional groups (Fig.26).
Fig. 26 Mechanism of MAGL inhibiton by carbamate, X = O
Finally, several studies have highlighted the most important structural features
needed to obtain novel MAGL inhibitors: a hydrophobic pharmacophoric group and
a linker connected with polar pharmacophore.
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Based on these data, in the laboratory where I performed my thesis work,
compounds with general structure A and B (Fig. 27) were previously synthesized.
These compounds are characterized by a pyridine ring with a carbamate (A), and an
urea (B) polar functionality (Fig. 27).
Fig. 27 Pyridine scaffold I; Carbamate derivatives A; Urea derivatives B
The above-mentioned compounds showed, after a preliminary assay, a moderate
inhibitory activity; in particular, urea derivatives (B) present percentages of MAGL
inhibition between 30 to 40 %, when were tested at a final concentration of 10 µM.
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During the first part of my thesis work, to the aim of increasing our understandings
about the features of inhibitor-enzyme interactions, and with the purpose of
improving MAGL inhibitory activity, novel potential MAGL inhibitors 5-9 were
planned modifying the structures of the referred compounds A and B (Fig. 28).
Fig.28 Structures of urea derivate 5, carbamate derivative 6, thiourea derivatives 7 and 12, and
dithiocarbamate derivate 13. Compounds 6 and 13 could not be synthesized.
Compounds 6 and 5 were designed in order to evaluate the influence of N-
methylation of exocyclic nitrogen of pyridine nucleus, in order to evaluate the
influence of a tertiary nitrogen on MAGL inhibition.
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These derivatives were prepared as showed in scheme 1.
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Scheme 1
Reagents and condition: (i) tert-butyl alcohol, di-tert-butyl dicarbonate, 25°C ; (ii) DMF,
NaH , CH3I, 0 °C to r.t.; (iii) AcOEt, 37%. HCl; .(iv) CH2Cl2,  triphosgene, (v), toluene,
triethylamine, aniline, 0 °C; (vi) toluene, triethylamine, phenol, 0 °C...
The commercial available 2-amino-5-bromo-pyridine 1 was treated with di-tert-
butyl dicarbonate, to give derivative 2, which was then subjected to a methylation
of the exocyclic nitrogen of the pyridine ring through a reaction with NaH and
CH3I. The obtained N-methylated.derivative 3 was then deprotected using 37% HCl
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to afford compound 4, which was used as starting material to synthetize both
derivatives 5 and 6 in two steps.. In particular, compounds 4 was treated with
triphosgene to give the corresponding acid chloride 4i which without purification
was treated  with aniline in presence of triethylamine to afford the urea derivative 5.
A similar procedure was used to obtain the carbamate derivative 6: the intermediate
4i was reacted with phenol in presence of triethylamine, but in these reaction
conditions the desired compound was not obtained.
Thiourea derivatives 7 and 12 and the dithiocarbamate derivative 13 (Fig. 28) were
designed in order to evaluate the influence of the replacement of the carbonyl
moiety with a thiocarbonyl function.
In particular, some studies demonstrated that the dithiocarbamate derivatives
present a high activity toward MAGL problaby because they could be involved in
covalent bond with either the catalytic Ser122, as all the carbamate derivatives do,
and with the Cys208 or Cys242, two noncatalytic cysteine residues, of the MAGL,
by means of the divalent sulfur.32
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Thiourea derivatives 7 and 12 were prepared as it is showed in scheme 2.
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Reagents and conditions: (i) toluene, phenylboronic acid, tetrakis, 2M Na2CO3; MW,
135°C, 5 bar; (ii) tert-butyl alcohol, di-tert-butyl dicarbonate, 25°C ; (iii) DMF, NaH ,
CH3I, 0 °C to r.t.; (iv) AcOEt, 37%. HCl; (v) EtOAc, 4-methoxy-isothiocyanate.
The Thiourea derivative 7 was obtained from the commercial available 2-amino-5-
bromo-pyridine that was reacted with 4-methoxy-phenyl isothiocyanate.
The thiourea derivative 8 was obtained starting from compound 1 that was firstly
treated with phenylboronic acid via a Suzuki-type cross coupling, using tetrakis as
catalyst and aqueous Na2CO3 as base. The reaction was heated in a microwave
reactor at 135 °C for 30 minutes to afford compound 8. Then, compound 8 was
treated with di-tert-butyl dicarbonate in tert-butyl alcohol to give the N-Boc-
Scheme 2
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derivative 10, which was reacted with NaH and CH3I, at 0 °C to afford the N-
methylated derivative 11. Compound 10 was deprotected using 37 % HCl and the
obtained secondary amine 13 was treated with 4-methoxy-phenyl-isothiocyanate,
affording compound 8.
The synthesis of compound 9 was planned, as it is reported in literature, by a two-
step pathway illustrated in fig. 27.
Fig.27 Syntheses of Dithiocarbamic Acid Sodium Salt and of the Dithiocarbamate Derivates trhough
Ullman-Type Reaction
This synthetic pathway consists in the Ullman-type coupling reaction between a
substituted iodobenzene and dithiocarbamic acid sodium salt, in presence of CuI
and N,N-dimethylglycine in DMF.
During my thesis work, the preparation of the dithiocarbamic acid sodium salt (9i
Scheme 4), necessary for the preparation of dithiocarbamic derivatives, was
attempted several times:
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1) Compound 5 dissolved in absolute EtOH or in acetone was treated with
aqueous NaOH and CS2 at 0 °C to r.t.
2) Compound 5 dissolved in MeOH was treated with aqueous NaOH and CS2 in
equal ratios and refluxed at 40 ° C for 5 h.
3) Compound 5 dissolved in THF was treated firstly with NaH and then with
CS2. The mixture was refluxed for 1 h.
All these attempts gave unsatisfying results, unlike was reported in literature.
Scheme 4
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In order to evaluate their inhibitory activity, the synthesized compounds were tested
using a HPLC-UV based assay, previously developed in our research laboratory.
This assay employs human recombinant MAGL as enzyme and 4‐nitro
phenylacetate (4-NPA) as its enzymatic substrate. The 4-NPA was reported to be a
good and safe MAGL substrate, and its interaction of with the enzyme leads to the
production of p-nitrophenol (PNP) as metabolite (Fig.29)
Fig. 29 Hydrolysis of 4‐NPA and release of PNP.
The assay is based on the chromatographic separation and subsequent absorbance
measurement of PNP, that is detected at the optimal wavelength of 315 nm (fig. 30).
MAGL activity was correlated to the concentration PNP, while the inhibitory
activity of the test compounds is been related to the residual enzyme activity.
Fig. 3  Chromatogram of MAGL enzymatic activity (black), and 4-NPA and PNP absorption spectra (red).
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The HPLC analysis conditions used in the developed method are:
 Stationary phase: VARIAN 150x4.6 mm INTERSIL 5μ;
 Mobile phase: composed of 53% MeOH and 47% 10mM ammonium acetate
buffer at pH 4;
 Flow: 0.7  mL / min;
 Detector UV: set at wavelengths of 315 nm;
 Synthesized compound concentration: 10 μM.
Moreover all the compounds need a pre‐incubation time, between the enzyme and
inhibitor, of 30 minutes at 37 °C and an incubation time of 10 minutes at 37 °C after
the substrate addition.
Compound Stucture
% of MAGL
residual
activity
% of MAGL
inhibition
(8) 100 0
(7)
55.53 44.47
(5) 82.04 17.96
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EXPERIMANTAL PART
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1. Equipments and methods
Structure of synthesized compound was verified by 1H NMR analysis. NMR spectra
were obtained with a Bruker 400MHz spectrometer. Chemical shift are reported in
parts per million downfield from tetramethylsilane and referenced to the solvent
residual peak. Coupling constants are reported in Hertz (Hz). Evaporation was
performed in vacuo by a rotating evaporator. All reactions was monitored by thin-
layer chromatography (TLC) using Merck aluminium silica gel (60 F254) sheets
that were visualized under a UV lamp (254 nm). Silica gel flash chromatography
was performed using silica gel (Kieselgel 40, 0.040-0.063 mm; Merck). Microwave
assisted reactions were run in a CEM Discover® LabMateTM microwave
synthesizer or in a Biotage initiator.
Chemistry: commercially available reagents were purchased from Sigma Aldrich or
Alfa Aesar, and used without purification.
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Tert-butyl (5-bromopyridin-2-yl)carbamate
(2)
Commercially available 2-amino-5-bromopyridine (1) (400 mg, 2.32 mmol) was
dissolved in tert-butanol (15,3 mL). To the resulting solution was added di-tert-
butyl dicarbonate (555 mg, 2.55mmol), and it was left under stirring, at room
temperature, for 24 hours.
After this time, the reaction was monitored by TLC and starting material was still
present, thus 1 eq of di-tert-butyl-dicarbonate (555 mg) was added, and the reaction
was left under stirring, at room temperature, for other 24 hours. Then the reaction
mixture was diluted with EtOAc and concentrated under reduce pressure. The crude
solid obtained was dissolved in EtOAc, washed repeatedly with water, dried over
anhydrous Na2SO4, filtered and concentrated under vacuum to afford a crude
residue that was purified by silica gel flash chromatography, using petroleum ether
(b,p, = 40-60 °C)/EtOAc 8: 1 as eluent, to give the pure compound (2) (300 mg, 1.1
mmol) as a white solid.
Yield: 75%
1H-NMR: (CDCl3) δ (ppm) 8.34 (d, J = 2 Hz, 1H, Py), 8.23 (bs, 1H), 7.92 (d, J =8.8
Hz, 1 H, Py), 7.75 (dd, J = 8.8 Hz, 2.4 Hz, 1H, Py), 1.54 (s, 9H).
63
Tert-butyl (5-bromopyridin-2-yl)(methyl)
carbamate
(3)
Compound 2 (250 mg, 1.41 mmol) was dissolved in anhydrous DMF (5,5 mL).
Then, the solution, kept under stirring at a temperature of 0 °C, is added Sodium
Hydride (NaH) (45.8 mg, 1.45 mmol), and allowed to react for 20 minutes. After,
CH3I (65 µL 1.56 mmol) was added and the reaction mixture was left at 0 °C for 30
minutes and, then, left to warm at room temperature for 1 h. After this time a new
addition of CH3I (0.75 eq, 33 µL) was necessary to induce the reaction to
completeness. Then, the mixture was diluted with water and extracted several times
with diethyl ether. The organic phase was washed with HCl 0.1 N, saturated
NaHCO3 and brine, and then dried over anhydrous Na2SO4, filtered and
concentrated under reduce pressure to afford bronze-coloured oil, compound 3 (200
mg 0.69 mmol) which was used in the following step without further purification.
Yield: 80%
1H-NMR: (CDCl3) δ (ppm) ) 8.44 (d, J = 2 Hz, 1H, Py), 7.75 (dd, J = 8.8 Hz, 2.4 Hz,
1H, Py), 7.62 (d, J =8.8 Hz, 1 H, Py), 3.74 (s, 3H),  1.54 (s, 9H)
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5-Bromo–N- Methyl-Pyridin-2-Amine
(4)
To a solution of compound 3 (200 mg , 0.69 mmol) in ethyl acetate (11.54 mL),
HCl (37 %, 2.26 mL, 27.6 mmol) was added and the resulting mixture was left
under stirring at room temperature for 1 hour. Then the solution was partitioned
between EtOAc and water, and the aqueous layer was neutralized with saturated
NaHCO3, until a white precipitate was observed and extracted several times with
ethyl acetate. The organic phase was then dried over anhydrous Na2SO4, filtered
concentrated under vacuo to give light grey solid, corresponding to compound 4
(133.33 mg, 0.71 mmol), which was used in the following step without further
purification.
Yield: 66.66%
1H-NMR: (CDCl3) δ (ppm) 8.07-8.05 (m, 1H, Py), 7.74 (d, J = 8.8 Hz, Py), 6.77 (dd,
J = 8.8 Hz, 2.4 Hz, 1H Py), 3.70 (bs, 1H), 1.84 (s, 3H)
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1-(5-Bromopyridin-2-yl)-1-methyl-3-phenylurea
(5)
To a stirred solution of compound 4 (200 mg, 1.08 mmol) in CH2Cl2 (1.8 mL)
(Et)3N (0.23 mL 3.24 mmol) was added at 0 °C. After, triphosgene (267 mg, 0.9
mmol) was added dropwise and the colour of the resulting mixture changed from
light yellow to intense purple. After 2 h at 0 °C, the obtained precipitate was filtered
and the filtrate concentrated under vacuum, yielding a violet solid, intermediate 4i,
(260 mg, 1.1 mmol) which was used in the following step without further
purification.
To a solution of compound 4i (130 mg, 0.55 mmol) in anhydrous toluene (1 mL)
(Et)3N (0.1 mL 1.37 mmol) was added, under a N2 atmosphere, at 0 °C, followed by
the slowly addiction of aniline (46 µL, 0.55 mmol). The reaction was left under
stirring, at room temperature, overnight. After the solution was filtered to remove
the precipitate corresponding to the byproduct diphenylurea, and the obtained
filtrate was concentrated under vacuo, to give the crude residue which was purified
by flash chromatography on silica gel using petroleum ether (b.p. = 40-60 °C)/ethyl
acetate 5:1 as eluent to afford the pure compound 5 (35 mg, 0.12 mmol) as a
yellowish solid.
Yield: 19.44%
1H-NMR: (CDCl3) δ (ppm) 8.41 (d, J = 2.4 Hz, 1H, Py), 7.84 (dd, J=8.8 Hz, 2.4 Hz,
1H, Py), 7.56-7.54 (m, 1H, Ph), 7.34-7.30 (m, 1H, Ph), 7.08 (m, 1H, Ph), 6.98 (d, 1H,
J= 8.8 Hz, Py), 3.46 (s, 3H).
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1-(5-Bromopyridin-2-yl)-3-(4-Methoxylphenyl)
Thiourea.
(7)
Commercially available 2-amino-5-bromopyridine 1 (300 mg, 1.75 mmol) was
dissolved in toluene (3 mL). Then 4-methoxy-phenyl-isothiocyanate (294 mg, 1.8
mmol) was added and the reaction was refluxed at 110 °C for 5 hours. After, a
white precipitate, corresponding to pure compound 7, was collected by filtration (40
mg, 0.12 mmol).
Yield: 13.33%
1H-NMR: (CDCl3) δ (ppm) 13.02 (bs, 1H), 10.92 (bs, 1H), 8.43 (d, J = 2.4 Hz, 1H,
Py), 8.03 (dd, J=8.8 Hz, 2.4 Hz, 1H, Py), 7.51-7.48 (m, 2H, Ph), 7.34-7.30 (m, 1H,
Ph), 7.24 (d, 1H, J= 8.8 Hz, Py), 6.95-6.93 (m, 2H, Ph), , 3.75 (s, 3H).
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5-Phenylpyridin-2-amine
(10)
Under a nitrogen atmosphere, benzenboronic acid (387.7 mg, 3.18 mmol) and 2 M
aqueous Na2CO3 (6.8 mL, 13.6 mmol) were added to a stirred solution of
commercially available 2-amino-5-bromopyridine (1) (500 mg, 2.89 mmol) and
tetrakis (triphenylphosphine) palladium (0) (167 mg, 0.14 mmol) in anhydrous
toluene (10 mL). The resulting mixture was heated under stirring at 135 °C in a
microwave reactor for 30 minutes.
Then, the reaction mixture was diluted with water and repeatedly extracted with
EtOAc. The organic phase was dried over anhydrous Na2SO4, filtered and
concentrated under reduced pressure to give a crude residue which was purified by
silica gel flash chromatography using n-hexane/EtOAc 1:1 as eluent to afford pure
compound 10 (230 mg, 1.35 mmol) as a yellow solid.
Yield: 69%
1H-NMR: (CDCl3) δ (ppm): 8.32(d, 1H, J=2.4Hz, pyridine-H H3), 7.67(dd, 1H,
J1=8.5Hz, J2=2.5Hz, pyridine-H H2), 7.51-7.49(m, 2H, phenyl-H ), 7.44-7.40(m,
2H, phenyl-H), 7.33-7.29(m,1H, phenyl-H), 6.57(d, 1H, J=8.5Hz, pyridine-H, H1)
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Tert-butyl (5-phenylpyridin-2-yl)-carbamate
(11)
Compound 10 (670 mg, 4.05 mmol) was dissolved in tert-butanol (26,3 mL). To the
resulting solution was added di-tert-butyl dicarbonate (975mg, 4.45mmol), and it
was left under stirring, at room temperature, for 24 hours.
After this time, the reaction mixture was diluted with EtOAc and concentrated
under reduce pressure to eliminate tert-butanol. The crude solid obtained was
dissolved in EtOAc, washed repeatedly with water, dried over anhydrous Na2SO4,
filtered and concentrated under vacuum to afford a crude residue that was purified
by silica gel flash chromatography, using petroleum ether (b,p, = 40-60 °C)/EtOAc
7: 1 as eluent, to give the pure compound 11 (480 mg, 1.77 mmol) as a white solid.
Yield: 71,64%
1H-NMR: (CDCl3) δ (ppm) 8.50 (d, J = 2.4 Hz, 1H, Py), 8.04 (d, 1H, J= 8.8 Hz, Py),
8.01 (bs, 1H), 7.89 (dd, J=8.8 Hz, 2.4 Hz, 1H, Py), 7.56-7.53 (m, 2H, Ph), 7.48-7.43
(m, 1H, Ph), 7.39-7.34 (m, 2H, Ph), , 1.54 (s, 9H).
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Tert-butyl methyl(5-phenylpyridin-2-yl)-
carbamate
(12)
Compound 11 (435 mg, 1.79 mmol) was dissolved in anhydrous DMF (10,5 mL).
Then, the solution, kept under stirring at a temperature of 0 °C, is added Sodium
Hydride (NaH) (89,7 mg 2.75 mmol), and allowed to react for 20 minutes. After,
CH3I (127 µL 2.06 mmol) was added and the reaction mixture was left at 0 °C for
30 minutes and, then, left to warm at room temperature for 1 h. After this time
mixture was diluted with water and extracted several times with diethyl ether. The
organic phase was washed with HCl 0.1 N, saturated NaHCO3 and brine, and then
dried over anhydrous Na2SO4, filtered and concentrated under reduce pressure to
afford bronze-coloured oil, compound 12 (380 mg 1.34 mmol) which was used in
the following step without further purification.
Yield: 87.35%
1H-NMR: (CDCl3) δ (ppm) 8.60 (d, J = 2.4 Hz, 1H, Py), 7.84 (dd, J=8.8 Hz, 2.4
Hz, 1H, Py), 7.76 (d, 1H, J= 8.8 Hz, Py), 7.56-7.54 (m, 2H, Ph), 7.48-7.43 (m, 1H,
Ph), 7.39-7.36 (m, 2H, Ph), 3.45 (s, 3H), 1.54 (s, 9H).
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N-methyl-5-phenylpyridin-2-amine
(13)
To a solution of compound 12 (900 mg , 3.16 mmol) in ethyl acetate (52.8 mL),
HCl (37 %, 10.4 mL, 126.4 mmol) was added and the resulting mixture was left
under stirring at room temperature for 1 hour. Then the solution was partitioned
between EtOAc and water, and the aqueous layer was neutralized with saturated
NaHCO3, until a white precipitate was observed and extracted several times with
ethyl acetate. The organic phase was then dried over anhydrous Na2SO4, filtered
concentrated under vacuo to give light grey solid, corresponding to compound 13
(550 mg,  2.89 mmol), which was used in the following step without further
purification.
Yield: 61,11%
1H-NMR: (CDCl3) δ (ppm) 8.35 (d, J = 2 Hz, 1H, Py), 7.70 (dd, J=8.8 Hz, 2.4 Hz,
1H, Py), 7.52-7.49 (m, 2H, Ph), 7.44-7.40 (m, 1H, Ph), 7.34-7.29 (m, 2H, Ph), 6.49
(d, 1H, J= 8.8 Hz, Py), 4.74 (bs, 1H), 2.97 (d, 3H), 1.54 (s, 9H).
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3-(4-methoxyphenyl)-1-methyl-1-(5-phenylpyridin-
2-yl) thiourea.
(8)
N-methyl-5-phenylpyridin-2-amine (13) (180 mg, 0.98 mmol) was dissolved in
toluene (2 mL). The 4-methoxy-isothiocyanate (166 mg, 1.02 mmol) was added to
the stirred and the mixture was refluxed at 120 °C for 48 hours. After this time, the
solution was washed repeatedly with water and extracted with ethyl acetate. The
organic phase was then dried over anhydrous Na2SO4, filtered and concentrated
under reduce pressure. The crude residue obtained is purified by flash
chromatography on silica gel using petroleum ether (b.p = 40-60 °C)/ethyl acetate
7:2 as eluent to give the pure compound 12 (50 mg, 0.152 mmol) as a white oil.
Yield: 27,78%
1H-NMR: (CDCl3) δ (ppm) 11.23 (bs, 1H), 8.77 (d, J = 2.8 Hz, 1H, Py), 8.16 (dd,
J=8.8 Hz, 2.8 Hz, 1H, Py), 7.75-7.72 (m, 2H, Ph), 7.52-7.48 (m, 4H, Ph), 7.43-7.39
(m, 2H, Ph), 7.32-
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5. BIOLOGICAL ASSAY
5.1 MAGL Inhibition HPLC Assay
5.1.1 Materials and methods
5.1.2 Reagents
• 4‐Nitrophenyl acetate (4‐NPA), Sigma Aldrich ®;
• p‐nitrophenol (PNP), Sigma Aldrich ®;
• Acetonitrile for HPLC, Sigma Aldrich ®;
• Acetic acid, Sigma Aldrich ®;
• Ammonium acetate (≥ 98%); Sigma Aldrich ®;
• EtOH absolute, Sigma Aldrich ®;
• anhydrous DMSO; Sigma Aldrich ®;
• Methanol for HPLC, Sigma Aldrich ®;
• MAGL Assay Buffer, Cayman Chemical ®;
• human recombinant MAGL, Cayman Chemical ®;
• MAGL Substrate (4‐NPA), Cayman Chemical ®;
5.2 Analytical Instruments
The analytical instrument used, was  a HPLC Thermo Finingam SCM 1000, with
P2000 Pump, UV 2000 detector and injector loop with 20 ml. The column used is a
Varian (150x4.6 mm) INTERSIL 5 μm.
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5.2.1 Instrumentation for the preparation of
aqueous solutions
Aqueous solutions were prepared through the use of water "bidistilled" (resistance
of 18.0 MQ) with ion exchange resins, and subsequently microfiltered with the
appliance MilliQ (Millipore Corporation, MA, USA).
5.2.2 Preparation of the mobile phase
Preparation of Ammonium Acetate Buffer
For each liter of solution are dissolved 0.77 g of ammonium acetate
(CH3COONH4, PM 77.08 g/mol) in 900 mL of MilliQ water under magnetic
stirring. The pH is adjusted, using a pH‐meter with glass electrode, to a value of 4
adding dropwise acetic acid (CH3COOH, 2M). The solution is then brought to
volume in a volumetric flask of one liter, and then filtered through a microporous
membrane made of polypropylene with an average diameter of 0.2 microns (PALL
Corporation, Michigan, USA) using a vacuum pump. During the period of
non‐use, the solution was stored at 3°C, and at the time of reuse has been
redissolved in warm water (30°C).
5.2.3 Preparation of solutions for the performance of
the assay
The solutions used for the test were prepared in accordance with what is described
by the kit Cayman Chemical ®. 32
a) Incubation Buffer: 3 mL of "MAGL Assay Buffer" are brought to a volume of 30
mL using H2O MilliQ filtered.
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b) MAGL human ricombinante: 30 µL of "MAGL Human Recombinant" are
diluted with 570 mL of incubation buffer.
c) Substrate (4‐NPA): It was originally used the sample provided by the company
(1.2 mL concentration 4.25 mM). Subsequently the same sample was prepared by
weighing 1.54 mg of 4‐PNA and dissolved in 2 mL of EtOH.
5.3 Inhibitory activity of compounds tested
The screening of the compounds was done using the following chromatographic
conditions:
• STATIONARY PHASE: VARIAN 150x4.6 mm INTERSIL 5μ;
• MOBILE PHASE: composed of 53% MeOH and 47% of buffer 10 mM
ammonium acetate at pH 4;
• FLOW: 0.7 mL / min;
• DETECTOR UV: set at a wavelength of 270 nm for 4‐postcode and 315 nm
for PNP;
The screening protocol provides the following step (Table 8):
1. Analysis of the "BLANK": to 80 µL of incubation buffer were added 5 µL of
EtOH and 5 µL of 4‐PNA. After stirring were incubated for 10 minutes at 37°C
and then 20 mL were analyzed by HPLC.
2. Initial determination (A.I) of the enzyme: to 75 µL of incubation buffer were
added 5 µL of enzyme and 5 µL of EtOH; after stirring the sample is placed in
preincubate for 30 minutes at 37 ° C and subsequently are added 5 µL of 4‐NPA
and are incubated for 10 minutes at 37 ° C. 20 µL were analyzed by HPLC.
3. Determination of compounds inhibitory activity: to 75 µL of buffer was added 5
µL of enzyme and 5 µL of inhibitor, were stirred and pre‐incubated for 30 minutes
at 37°C.
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After that were added 5 µL of 4‐PNA, stirred and incubated for 10 minutes at
37°C. Finally, 20 mL were analyzed by HPLC.
BUFFE
R
MAG
L
SOLVEN
T
INHIBITO
R
SUBSTRAT
E
(4-PNP)
100%
INITIAL
ACTIVITY
75µL 5 µL 5 µL …….. 5 µL
BLANK 80 µL …….. 5 µL …….. 5 µL
INHIBITO
R 75 µL 5 µL …….. 5 µL 5 µL
Tab. 5 Summary table of the screening protocol
6. SCREENING OF COMPOUNDS SYNTHESIZED
This method (tab. 4) was applied for the screening of compounds synthesized
during my thesis. All compounds were tested in duplicate at a concentration of 10
μM.
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1.1 Compound (8)
7.65 mg (MW = 306.16 g/mol) were dissolved in 1mL of dimethyl sulfoxide
(DMSO) to obtain a solution 24986.93 µM (A) which was diluted with EtOH in
order to obtain a concentration of 185.081 µM (D) (tab. 5).
Taken volume
(µL)
Final volume
(mL) EtOH
Final
concentration
(µM)
Dilution name
100 µL of A 0.4 4997,2 B
100 µL of B 0.2 1665.73 C
100 µL of C 0.2 185,081 D
                                                       Tab. 5 diluition of compound (6i)
1.2 Compound (7)
1.33 mg (MW = 349.45 g/mol) were dissolved in 1mL of dimethyl sulfoxide
(DMSO) to obtain a solution 3805,981 µM (A) which was diluted with EtOH in
order to obtain a concentration of 190.29 µM (C) (tab. 6).
Taken volume
(µL)
Final volume
(mL) EtOH
Final
concentration
(µM)
Dilution name
100 µL of A 0.4 761.196 B
100 µL of B 0.3 190.29 C
Tab. 6 Dilution of compound (7)
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1.3 Compound (5)
1.04 mg (MW = 274.32 g/mol) were dissolved in 1mL of dimethyl sulfoxide
(DMSO) to obtain a solution 3791.19 µM (A) which was diluted with EtOH in
order to obtain a concentration of 189.55 µM (C) (tab. 7).
Taken volume
(µL)
Final volume
(mL) EtOH
Final
concentration
(µM)
Dilution name
100 µL of A 0.4 758.238 B
100 µL of B 0.3 189.559 C
Tab.7 Dilution of compound (7)
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